VCTX210 (formerly PEC-QT™) is an investigational allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for treatment of type 1 diabetes. VCTX210 is designed to engineer ViaCyte’s CyT49 pluripotent human stem cell line via CRISPR Therapeutics’ gene editing technology to avoid destruction by the patient’s immune system, potentially eliminating the need for chronic immunosuppressants. If VCTX210 is found to be safe and immune evasive, the trial may expand to assess therapeutic dosing . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge